Guiyang Xintian Pharmaceutical Co.,Ltd. (SHE:002873)
China · Delayed Price · Currency is CNY 8.62
-0.11 (-1.26%)
Sep 2, 2026, 3:04 PM CST
SHE:002873 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 2,054 | 2,334 | 2,190 | 2,868 | 3,339 | 3,224 | |
Market Cap Growth | -27.37% | 6.57% | -23.62% | -14.13% | 3.58% | 72.48% |
Enterprise Value | 2,462 | 2,767 | 2,805 | 3,335 | 3,673 | 3,456 |
Last Close Price | 8.73 | 9.89 | 9.34 | 12.18 | 14.06 | 13.91 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 246.02 | 256.18 | 41.86 | 35.46 | 29.94 | 32.04 |
Forward PE | - | 23.52 | 23.52 | 18.74 | 20.49 | - |
PS Ratio | 2.84 | 3.11 | 2.55 | 3.01 | 3.07 | 3.32 |
PB Ratio | 1.61 | 1.86 | 1.83 | 2.58 | 2.98 | 3.62 |
P/TBV Ratio | 1.76 | 2.05 | 2.02 | 2.79 | 3.22 | 4.01 |
P/FCF Ratio | 36.04 | 72.62 | 82.10 | - | - | 173.24 |
P/OCF Ratio | 16.23 | 27.88 | 24.85 | 36.87 | 44.04 | 25.94 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 3.40 | 3.69 | 3.27 | 3.50 | 3.38 | 3.56 |
EV/EBITDA Ratio | 40.38 | 49.63 | 31.02 | 28.38 | 23.64 | 23.30 |
EV/EBIT Ratio | 104.93 | 121.01 | 48.26 | 34.32 | 28.09 | 27.30 |
EV/FCF Ratio | 43.20 | 86.08 | 105.13 | - | - | 185.73 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.46 | 0.53 | 0.47 | 0.54 | 0.43 | 0.48 |
Debt / EBITDA Ratio | 9.71 | 11.05 | 5.87 | 5.00 | 3.11 | 2.88 |
Debt / FCF Ratio | 10.39 | 20.81 | 21.00 | - | - | 23.10 |
Net Debt / Equity Ratio | 0.32 | 0.39 | 0.37 | 0.42 | 0.34 | 0.31 |
Net Debt / EBITDA Ratio | 7.15 | 8.88 | 4.89 | 3.95 | 2.48 | 1.87 |
Net Debt / FCF Ratio | 7.16 | 15.40 | 16.57 | -19.39 | -7.22 | 14.90 |
Asset Turnover | 0.37 | 0.37 | 0.44 | 0.51 | 0.65 | 0.63 |
Inventory Turnover | 1.37 | 1.36 | 1.40 | 1.19 | 1.64 | 1.96 |
Quick Ratio | 0.91 | 1.25 | 0.97 | 0.79 | 0.81 | 1.03 |
Current Ratio | 1.28 | 1.71 | 1.28 | 1.15 | 1.22 | 1.33 |
Return on Equity (ROE) | 0.67% | 0.74% | 4.53% | 7.24% | 11.08% | 11.71% |
Return on Assets (ROA) | 0.74% | 0.70% | 1.88% | 3.24% | 4.86% | 5.17% |
Return on Invested Capital (ROIC) | 0.96% | 1.26% | 3.11% | 5.51% | 8.98% | 10.34% |
Return on Capital Employed (ROCE) | 1.50% | 1.30% | 4.00% | 7.20% | 9.80% | 11.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 0.40% | 0.39% | 2.39% | 2.82% | 3.34% | 3.12% |
FCF Yield | 2.77% | 1.38% | 1.22% | -0.83% | -1.60% | 0.58% |
Dividend Yield | 0.36% | 0.30% | 1.07% | 0.57% | 0.71% | 0.62% |
Payout Ratio | 307.50% | 454.63% | 67.01% | 52.59% | 30.81% | 30.15% |
Buyback Yield / Dilution | -1.95% | -6.87% | 9.91% | -0.41% | 0.41% | -1.34% |
Total Shareholder Return | -1.59% | -6.57% | 10.98% | 0.16% | 1.12% | -0.73% |